Mesalazine rectal foam - Giuliani
Alternative Names: Asacol foam - Giuliani; Mesalamine rectal foam; SPD 480Latest Information Update: 02 Oct 2021
At a glance
- Originator Giuliani
- Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Ulcerative colitis
Most Recent Events
- 28 Jul 2005 Discontinued - Phase-II for Ulcerative colitis in USA (Rectal)
- 16 Aug 2004 SPD 480 is available for licensing in Japan (http://ww7.investorrelations.co.uk/shirepharma/index.jsp)
- 10 Apr 2003 Phase-II clinical trials in Ulcerative colitis in USA (Rectal)